Calidi Biotherapeutics closed at $0.68 on Nov 5, down 6.98%, 97.4% below its 52-week closing high. Volume of 32.6K shares was 0.68× its 20-day average (below normal).
Split-adjusted performance: -32.8% over one month, -80.4% over six months.
Short interest was 164.3K shares at the Oct 15 settlement, down 29.6% from the prior report (0.9% of float, 4.2 days to cover).
No reported quarters with price history yet.
Percentile among 139 companies (100 = best)
Industry medians: 6-month return −24.8%, revenue growth +8.5%, net margin −226.4%, P/E 21.0×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| CLDICalidi Biotherapeutics | $0.6790 | −6.98% | −80.4% | — | — | — | $1.8M | |
| VIVSVivoSim Labs | $0.1415 | −7.03% | −90.0% | −51.4% | −7433.3% | — | $1.9M | Compare |
| CRISCuris | $0.8500 | −23.42% | −92.6% | −100.0% | — | — | $2.1M | Compare |
| SLXNSilexion Therapeutics | $0.1438 | −6.32% | −97.2% | — | — | — | $2.1M | Compare |
| HLSQTessera Defense and Homeland Security | $0.1241 | −13.82% | — | — | — | — | $2.6M | Compare |
| LIMNLiminatus Pharma | $2.63 | −5.88% | −73.8% | — | — | — | $3.5M | Compare |
| PMCBPharmaCyte Biotech | $0.3752 | −1.52% | −53.1% | — | — | — | $4.0M | Compare |
| CELZCreative Medical Technology Holdings | $0.6059 | −7.05% | −73.5% | — | — | — | $4.6M | Compare |
| AIMAIM ImmunoTech | $0.1521 | −5.53% | −72.8% | +4.0% | −26876.9% | — | $6.1M | Compare |
Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
